Browsing by Subject "Breast Cancer"
Now showing items 1-11 of 11
-
Combination Drug Discovery in the Treatment of Multidrug-resistant Preclinical Models of Breast Cancer
(2021-11-15)Therapeutic resistance is the culprit behind most cancer-related relapse and death, accounting for over 90% chemotherapeutic intervention failures. To combat the genetic and phenotypical abnormalities associated with ... -
DEVELOPMENT AND CHARACTERIZATION OF T-SLICE: A CANCER MODELING PLATFORM TO MODEL IMPORTANT FEATURES OF THE TUMOUR MICROENVIRONMENT IN VITRO
(2022-07-27)The tumour microenvironment is composed of several types of non-cancerous cells (e.g., cancer-associated fibroblasts, endothelial cells, immune cells), extracellular matrix proteins, and cell signaling molecules. The various ... -
THE EFFECTS OF SOLUTE CARRIER ORGANIC ANION TRANSPORTERS ON JADOMYCIN PHARMACOLOGY IN BREAST CANCER
(2018-08-29)Breast cancer is the most commonly diagnosed cancer in women, and often becomes multidrug-resistant (MDR). Jadomycins are experimental chemotherapeutics that maintain cytotoxicity in MDR breast cancer cells and investigating ... -
EVALUATING INHIBITION OF DNA METHYLATION AND ALDH1A3 AS BREAST CANCER THERAPIES
(2020-09-01)Breast cancer is the most common form of cancer among Canadian women. Patients with triple-negative breast cancer (TNBC) have poor prognoses, with inherently more aggressive disease and limited treatment options. New ... -
Exercise to Prevent Anthracycline-Induced Cardiotoxicity (EXACT2.0) in Females with Breast Cancer
(2022-08-16)The cardioprotective effects of aerobic exercise (AE) in mitigating anthracycline (AC)-induced cardiotoxicity in females with breast cancer (BC) remain unclear. This study investigated the impact of a 24-week home-based ... -
The Flavonoid Apigenin Inhibits Inducible Programmed Death Ligand 1 Expression by Breast Cancer Cells
(2018-02-12)Programmed death ligand 1 (PD-L1) is a T cell inhibitory molecule expressed by activated T cells and antigen presenting cells, as well as by various tumor types. PD-L1 expression is believed to contribute to immune evasion ... -
HORMONAL REGULATION OF CARBOXYPEPTIDASE-D GENE TRANSCRIPTION IN BREAST CANCER CELLS
(2015-04-28)Carboxypeptidase-D (CPD), bound to the plasma membrane, cleaves C-terminal arginine from extracellular substrates. Arginine is converted to nitric oxide (NO), which can promote tumour progression. We have previously ... -
Mitigating Cardiotoxicity: The Effects of Physical Activity on Echocardiographic Parameters and the Metabolome in Breast Cancer Patients Receiving Anthracycline Treatment
(2023-07-28)Metabolomic profiling is a novel technique to identify anthracycline-induced cardiotoxicity (CTX). Higher physical activity levels may mitigate this damage. Therefore, the primary objectives of this thesis were to determine ... -
Need for Navigation and Utilization of Cancer Patient Navigators (CPNs) among Breast Cancer Patients in Nova Scotia
(2019-09-03)Background: The Cancer Patient Navigator (CPN) program aims to reduce burdens of care coordination, emotional stress and logistical challenges on cancer patients in Nova Scotia (NS). There is concern that some patients ... -
A PILOT STUDY OF RESISTANCE EXERCISE FREQUENCY IN BREAST AND OVARIAN CANCER SURVIVORS
(2014-12-16)A large body of research suggests exercise is effective for improving fitness, quality of life (QOL), and fatigue in cancer survivors. Despite evidence in support of exercise, few studies have rigorously evaluated exercise ... -
TRANSCRIPTION FACTOR EB REGULATES APOPTOSIS, DNA REPAIR, AND CELL PROLIFERATION IN TRIPLE-NEGATIVE BREAST CANCER CELLS
(2022-05-03)Breast cancer is the leading cause of cancer-related death among women in Canada. Molecular heterogeneity among breast cancer patients dictates survival outcomes and treatment selection, with triple-negative breast cancer ...